NCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma No drug interventions treatment 1 not_yet_recruiting NCT05852717
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma treatment 2 recruiting NCT05563844
Study of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL) No drug interventions other 2 recruiting NCT05526313
Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant No drug interventions other 1 completed NCT02898870
Occupational Exposure to Pesticides in the Prognosis of Lymphomas No drug interventions Not Available Not Available terminated NCT03597685
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes No drug interventions Not Available Not Available completed NCT02226965
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) treatment 2 completed NCT04745559
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy treatment 2 recruiting NCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas treatment 1 suspended NCT00286832
Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV No drug interventions Not Available Not Available completed NCT00268853
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin treatment 2 completed NCT00144807
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma treatment 2 completed NCT00942409
Study of Repeat Intranodal Injections of Ad-ISF35 treatment 2 terminated NCT01685606
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma No drug interventions treatment 2 terminated NCT00949741
Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients No drug interventions Not Available Not Available completed NCT00598624
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) treatment 2 unknown_status NCT00140595
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 treatment 3 completed NCT01300026
AMG 319 Lymphoid Malignancy FIH No drug interventions treatment 1 completed NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT00225212
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma treatment 2 completed NCT02374333
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy No drug interventions treatment 1 completed NCT02819583
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma No drug interventions treatment 1 / 2 unknown_status NCT00791011
Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat treatment 1 completed NCT01234467
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma treatment 2 completed NCT01859819
Treatment for Advanced B-Cell Lymphoma treatment 2 completed NCT00591630
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation treatment 2 completed NCT04859920
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region No drug interventions Not Available Not Available completed NCT01943682
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma No drug interventions treatment 1 completed NCT00275431
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies treatment 2 completed NCT00140660
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma treatment 3 terminated NCT00169195
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma treatment 2 completed NCT02892695
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma treatment 1 / 2 unknown_status NCT00144755
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma treatment 3 completed NCT01724021
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a treatment 3 completed NCT02141451
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL treatment 1 / 2 completed NCT00398372
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment Not Available Not Available completed NCT02955823
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL treatment 2 completed NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) treatment 2 / 3 recruiting NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT05546268
Study of Oral MRT-2359 in Selected Cancer Patients treatment 1 / 2 recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 recruiting NCT04088890
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies treatment 1 active_not_recruiting NCT05233033
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL No drug interventions treatment 1 suspended NCT06150053
Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL No drug interventions Not Available Not Available completed NCT04855253
Study of E7777 Prior to Kymriah for R/R DLBCL treatment 1 / 2 recruiting NCT03527147
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) treatment 1 completed NCT04002947
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05552937
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL treatment 2 recruiting NCT04293900
Diet, Physical Activity and Body Composition Changes During R-CHOP No drug interventions Not Available Not Available withdrawn NCT05381506
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma treatment 2 not_yet_recruiting NCT03954106
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity treatment 2 terminated NCT05498636
SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression treatment 1 / 2 not_yet_recruiting NCT04082936
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 terminated NCT03287817
CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma treatment 1 / 2 completed NCT04512716
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma No drug interventions treatment 0 recruiting NCT04974216
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older treatment 2 recruiting NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT04332822
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma treatment 3 recruiting NCT03672682
SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers? No drug interventions Not Available Not Available completed NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL No drug interventions treatment 1 withdrawn NCT05414162
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy No drug interventions Not Available Not Available recruiting NCT02698189
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) treatment 1 terminated NCT03758989
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma treatment 2 recruiting NCT03205046
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies treatment 1 / 2 terminated NCT04432714
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement treatment 1 / 2 recruiting NCT06521255
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 3 recruiting NCT01287923
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans No drug interventions Not Available Not Available completed NCT04300803
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL Not Available Not Available approved_for_marketing NCT01563302
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers No drug interventions treatment 1 / 2 completed NCT04842487
R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study treatment 2 unknown_status NCT03356054
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse treatment 1 / 2 recruiting NCT04594798
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL treatment 2 recruiting NCT05852028
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma Not Available Not Available recruiting NCT05653271
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies treatment 1 recruiting NCT04566978
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) diagnostic 0 active_not_recruiting NCT06569485
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients prevention 2 recruiting NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT01205737
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects treatment 1 completed NCT05487170
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) No drug interventions treatment 1 / 2 recruiting NCT03123718
High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL prevention 3 unknown_status NCT05253118
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) treatment 2 recruiting NCT02702141
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT03731234
Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance treatment 2 recruiting NCT03225924
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy treatment 1 / 2 terminated NCT05039658
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) treatment 1 unknown_status NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies No drug interventions treatment 1 recruiting NCT03463057
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL treatment 2 active_not_recruiting NCT04994626
Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies treatment 2 not_yet_recruiting NCT01285765
Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients treatment 3 completed NCT05093140
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL treatment 2 not_yet_recruiting NCT03943901
Split-Dose R-CHOP for Older Adults With DLBCL treatment 2 active_not_recruiting NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT03628612
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells No drug interventions other 2 enrolling_by_invitation NCT02488512
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas treatment 2 terminated NCT02889523
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy treatment 1 / 2 active_not_recruiting NCT05328102
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) treatment 2 terminated NCT04735471
A Phase 1 Study of ADI-001 in B Cell Malignancies treatment 1 active_not_recruiting NCT04696692
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma No drug interventions other Not Available active_not_recruiting NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma treatment 1 recruiting NCT04594642
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma No drug interventions treatment 1 recruiting NCT04529772
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) treatment 3 active_not_recruiting NCT05365659
IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas No drug interventions treatment 1 recruiting NCT05179603
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] treatment 2 terminated NCT05192486
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) No drug interventions treatment 1 / 2 recruiting NCT05934838
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas treatment 1 recruiting NCT06131801
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution No drug interventions Not Available Not Available active_not_recruiting NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. treatment 1 recruiting NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) treatment 1 / 2 recruiting NCT06503263
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL treatment 2 recruiting NCT06508658
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 3 recruiting NCT06589089
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy No drug interventions treatment 2 not_yet_recruiting NCT06588205
Exploring the Clinical Impact of MYC Aberrations and Their Relationship with Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade C Cell Lymphoma No drug interventions Not Available Not Available not_yet_recruiting NCT06594640
R-CMOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma treatment 1 / 2 recruiting NCT05923502
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Not Available Not Available not_yet_recruiting NCT05169203
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study No drug interventions Not Available Not Available completed NCT04978584
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study treatment 2 recruiting NCT04491721
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL No drug interventions Not Available Not Available enrolling_by_invitation NCT04361279
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL treatment 3 completed NCT04263584
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL treatment 2 active_not_recruiting NCT05871684
A Combination Study of CAR-T Therapy in r/r B-NHL No drug interventions treatment 2 recruiting NCT05694364
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies treatment 1 recruiting NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies treatment 1 completed NCT02890602
Erythropoietin for Management of Anemia Caused by Chemotherapy supportive_care 2 completed NCT03028103
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients treatment 1 completed NCT02216890
Safety Study of SGN-CD70A in Cancer Patients No drug interventions treatment 1 completed NCT01846390
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma treatment 1 completed NCT01499303
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer treatment 2 completed NCT01369784
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT01279902
Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL treatment 2 unknown_status NCT00553943
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis treatment 2 completed NCT00386321
Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma treatment 2 terminated NCT06573099
A Real-World Study on Extranodal Lymphoma No drug interventions Not Available Not Available not_yet_recruiting NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities treatment 2 not_yet_recruiting NCT06516978
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL treatment 2 not_yet_recruiting NCT06530511
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients With Treatment-naive Non-GCB DLBCL treatment 2 not_yet_recruiting NCT06451497
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors No drug interventions other 1 recruiting NCT06441097
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL treatment 2 not_yet_recruiting NCT06392763
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data No drug interventions Not Available Not Available completed NCT06352242
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? No drug interventions other Not Available recruiting NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans No drug interventions Not Available Not Available not_yet_recruiting NCT06213636
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). No drug interventions treatment 1 / 2 recruiting NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT06005870
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression treatment 2 recruiting NCT05958134
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL No drug interventions Not Available Not Available completed NCT05940051
Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05934097
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma treatment 1 withdrawn NCT05820841
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma treatment 3 recruiting NCT05715606
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research No drug interventions treatment 0 recruiting NCT05659628
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL treatment 1 recruiting NCT05633615
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05518383
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 treatment 4 recruiting NCT05290337
ZR-CHOP in DLBCL With Specific Gene Abnormality treatment 2 recruiting NCT05265975
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL treatment 1 / 2 recruiting NCT05153330
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL No drug interventions treatment 1 recruiting NCT05108805
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting No drug interventions supportive_care Not Available active_not_recruiting NCT05048732
Imaging Apoptosis for Lymphoma Treatment Response No drug interventions diagnostic 0 terminated NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04914741
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) treatment 1 / 2 active_not_recruiting NCT04787263
CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML No drug interventions treatment 1 / 2 recruiting NCT04775745
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. No drug interventions treatment 1 recruiting NCT04974996
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) treatment 1 withdrawn NCT04661007
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) treatment 1 / 2 recruiting NCT04659434
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL treatment 2 not_yet_recruiting NCT04610970
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） No drug interventions treatment 2 unknown_status NCT04526834
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma No drug interventions treatment 1 active_not_recruiting NCT04517435
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT04476459
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL treatment 1 / 2 unknown_status NCT04460248
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients with Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 active_not_recruiting NCT04404283
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL treatment 3 active_not_recruiting NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT04319237
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes No drug interventions Not Available Not Available active_not_recruiting NCT04323657
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia treatment 1 / 2 completed NCT04282018
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab treatment 1 / 2 active_not_recruiting NCT06323447
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia No drug interventions Not Available Not Available not_yet_recruiting NCT05144009
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 completed NCT04254107
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer treatment 1 terminated NCT04231448
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL treatment 3 active_not_recruiting NCT04189952
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma treatment 2 terminated NCT04176913
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 terminated NCT04150328
Lenalidomide Monotherapy in R/R DLBCL No drug interventions Not Available Not Available completed NCT04134936
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL treatment 1 completed NCT04018248
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) treatment 1 active_not_recruiting NCT03999658
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies treatment 2 withdrawn NCT03999697
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies No drug interventions treatment 1 unknown_status NCT03955783
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies treatment 1 active_not_recruiting NCT03884998
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma treatment 1 active_not_recruiting NCT03876028
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients treatment 1 terminated NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT03797261
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies treatment 1 terminated NCT03749018
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma treatment 2 active_not_recruiting NCT03736616
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL treatment 2 unknown_status NCT03677128
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment No drug interventions health_services_research Not Available completed NCT03656835
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma No drug interventions diagnostic Not Available recruiting NCT03630159
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients treatment 1 completed NCT03543813
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL No drug interventions treatment 1 / 2 completed NCT03530683
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma treatment 1 terminated NCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies treatment 1 completed NCT03106428
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 completed NCT03162536
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) treatment 1 / 2 active_not_recruiting NCT04624971
A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era No drug interventions Not Available Not Available unknown_status NCT05022797
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS treatment 2 terminated NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma treatment 1 / 2 recruiting NCT05257018
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse treatment 2 recruiting NCT05255354
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy No drug interventions Not Available Not Available recruiting NCT05444322
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma No drug interventions treatment 0 recruiting NCT05455697
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma treatment 1 / 2 recruiting NCT05221645
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05541328
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel No drug interventions Not Available Not Available completed NCT05746858
Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA) No drug interventions Not Available Not Available not_yet_recruiting NCT05749549
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers No drug interventions treatment 1 / 2 active_not_recruiting NCT06290622
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL treatment 1 withdrawn NCT06290817
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI treatment 2 recruiting NCT05883709
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL Not Available Not Available not_yet_recruiting NCT05918809
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings No drug interventions Not Available Not Available completed NCT05896163
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. treatment 1 / 2 recruiting NCT04316624
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy No drug interventions treatment 1 completed NCT04425824
Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma treatment 2 unknown_status NCT04423549
Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product No drug interventions Not Available Not Available terminated NCT03399747
Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma No drug interventions treatment 2 enrolling_by_invitation NCT03229616
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT treatment 2 / 3 unknown_status NCT03255096
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 treatment 1 completed NCT03201471
Chidamide With R-CHOP Regimen for DLBCL Patients treatment 2 unknown_status NCT03246906
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation treatment 2 active_not_recruiting NCT03121456
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma No drug interventions diagnostic Not Available active_not_recruiting NCT03079947
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients No drug interventions Not Available Not Available unknown_status NCT05428670
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. treatment 2 recruiting NCT05432635
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT02752815
Reduced Chemotherapy in Low Risk DLBCL treatment 4 active_not_recruiting NCT02753647
Chidamide Plus R-CHOP in Elderly DLBCL treatment 2 unknown_status NCT02756247
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma treatment 1 completed NCT02758925
CyBeR Association in Relapsed/Refractory DLBCL treatment 2 unknown_status NCT02777736
CNS Prophylaxis in Diffuse Large B-cell Lymphoma prevention 3 unknown_status NCT02815397
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma treatment 2 terminated NCT02855359
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma treatment 2 terminated NCT02981745
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia No drug interventions treatment 1 / 2 unknown_status NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers treatment 1 / 2 terminated NCT02793583
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma treatment 2 / 3 terminated NCT02900651
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT02708732
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) No drug interventions Not Available Not Available completed NCT02692248
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation treatment 2 unknown_status NCT02617485
MabionCD20 Compared to MabThera in Lymphoma Patients treatment 3 completed NCT02549651
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) treatment 1 completed NCT02449278
The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma treatment 3 recruiting NCT02542111
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL treatment 2 unknown_status NCT02391116
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 completed NCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas treatment 1 / 2 completed NCT02399085
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL treatment 2 completed NCT02374424
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients No drug interventions treatment 2 terminated NCT02227251
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 recruiting NCT02060435
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma No drug interventions Not Available Not Available completed NCT01949818
Treatment of Diffuse Large B Cell Lymphoma treatment 4 unknown_status NCT01914718
Dose-adjusted EPOCH-R in MYC Positive DLBCL treatment 2 terminated NCT01848132
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. treatment 2 completed NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib) treatment 3 enrolling_by_invitation NCT01679119
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy treatment 2 completed NCT01670370
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. treatment 2 unknown_status NCT01562977
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL treatment 2 completed NCT01470456
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 2 completed NCT01423539
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) treatment 2 withdrawn NCT01321541
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant treatment 3 completed NCT01226849
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma treatment 1 completed NCT01202448
Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma No drug interventions diagnostic Not Available completed NCT01181271
Tandem Auto-Allo Transplant for Lymphoma treatment 2 completed NCT01177397
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma treatment 1 / 2 completed NCT01087424
Mini-CHOP and Rituximab in Patients Aged Over 80 Years No drug interventions treatment 2 completed NCT01030900
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas treatment 2 completed NCT01040871
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma treatment 2 completed NCT01009970
Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma treatment 2 unknown_status NCT00968656
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1 diagnostic 1 completed NCT00902525
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma treatment 2 terminated NCT00918463
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 terminated NCT00869999
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma treatment 2 completed NCT00831597
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 2 completed NCT00799513
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma treatment 2 completed NCT00790036
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy prevention 3 completed NCT00754117
Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) No drug interventions Not Available Not Available completed NCT00645359
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available terminated NCT00474188
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 2 terminated NCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies No drug interventions treatment 1 completed NCT04052061
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma treatment 1 withdrawn NCT04058470
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma treatment 1 / 2 recruiting NCT06186986
CD30 Imaging in Diffuse Large B-cell Lymphoma treatment 3 not_yet_recruiting NCT06539195
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) No drug interventions treatment 2 recruiting NCT06549361
A Retrospective Study on Extranodal DLBCL No drug interventions Not Available Not Available completed NCT06522555
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma treatment 3 recruiting NCT06517511
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) treatment 2 recruiting NCT06424379
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. No drug interventions Not Available Not Available active_not_recruiting NCT06355401
Maintenance Hormonal Therapy and DLBCL treatment 2 / 3 not_yet_recruiting NCT06249191
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma treatment 1 / 2 recruiting NCT06176729
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients treatment 2 recruiting NCT06149169
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma treatment 2 active_not_recruiting NCT06081478
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT05990985
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. treatment Not Available not_yet_recruiting NCT05940064
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05954910
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma Not Available Not Available recruiting NCT05809180
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients treatment Not Available recruiting NCT05784987
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma treatment Not Available not_yet_recruiting NCT05725720
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy No drug interventions Not Available Not Available recruiting NCT05658562
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL treatment 1 / 2 recruiting NCT05645744
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Not Available Not Available terminated NCT05660395
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) basic_science 1 recruiting NCT05660967
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma treatment 2 recruiting NCT05512390
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 1 recruiting NCT05498259
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL treatment 2 recruiting NCT05464329
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma treatment 1 recruiting NCT05377307
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy No drug interventions Not Available Not Available recruiting NCT05348213
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05290090
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL treatment 2 recruiting NCT05298293
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma No drug interventions prevention Not Available not_yet_recruiting NCT05280626
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP treatment 2 not_yet_recruiting NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia No drug interventions treatment 2 recruiting NCT05269914
Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL No drug interventions treatment Not Available unknown_status NCT05164770
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma treatment 3 recruiting NCT05121103
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma No drug interventions treatment 1 recruiting NCT05097443
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma treatment 3 recruiting NCT04911478
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells No drug interventions Not Available Not Available enrolling_by_invitation NCT04914143
the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After Chemotherapy No drug interventions treatment Not Available unknown_status NCT04928573
Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab No drug interventions Not Available Not Available completed NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT04844866
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients treatment 2 active_not_recruiting NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT04726787
RadiothErapy priMIng for CAR-T No drug interventions treatment Not Available active_not_recruiting NCT04726995
DLBCL Treatment in Children and Adolescents No drug interventions Not Available Not Available completed NCT04663347
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) treatment 1 / 2 recruiting NCT04661943
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma treatment 2 unknown_status NCT04668365
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma treatment 2 recruiting NCT06271369
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. No drug interventions Not Available Not Available completed NCT04604067
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. treatment 2 recruiting NCT04544059
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma prevention 2 not_yet_recruiting NCT04535102
POLA+BR for Relapsed or Refractory DLBCL treatment 2 withdrawn NCT04491370
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma treatment 1 / 2 recruiting NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL treatment 1 / 2 unknown_status NCT04503538
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity No drug interventions supportive_care Not Available withdrawn NCT04500561
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial treatment 1 / 2 unknown_status NCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers No drug interventions treatment 1 active_not_recruiting NCT04354402
Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL No drug interventions Not Available Not Available completed NCT04323956
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma treatment 1 active_not_recruiting NCT04186520
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT04182204
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 3 active_not_recruiting NCT04160442
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL No drug interventions health_services_research Not Available completed NCT04112238
ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT04094311
Study of Out of Specification for Tisagenlecleucel treatment 3 recruiting NCT04089215
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma No drug interventions treatment 2 active_not_recruiting NCT03990961
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) treatment 2 active_not_recruiting NCT03995147
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma treatment 2 recruiting NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma treatment 1 active_not_recruiting NCT03843294
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma treatment 1 active_not_recruiting NCT03833180
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) treatment 1 completed NCT03797170
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available active_not_recruiting NCT03800095
Early Palliative Care for Patients With Haematological Malignancies No drug interventions treatment 3 unknown_status NCT03777085
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) treatment 3 unknown_status NCT03720457
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. No drug interventions treatment 1 unknown_status NCT03664336
Refractory Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT03677154
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT03676504
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR treatment 1 / 2 recruiting NCT03610061
A Trial of Radiotherapy and Durvalumab in DLBCL and FL treatment 1 completed NCT03576443
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma treatment 2 completed NCT03513601
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma treatment 4 unknown_status NCT03520920
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) treatment 2 completed NCT03213977
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL No drug interventions treatment 3 active_not_recruiting NCT04622579
Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years treatment 2 unknown_status NCT04555811
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL treatment 1 completed NCT04697160
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL No drug interventions Not Available Not Available completed NCT04833504
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma No drug interventions Not Available Not Available completed NCT05020392
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma treatment 3 recruiting NCT05575973
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma treatment 2 not_yet_recruiting NCT05618028
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets No drug interventions treatment 1 recruiting NCT05412290
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma treatment 1 recruiting NCT05130489
CAR T Cell Therapy Related Cardiovascular Outcomes No drug interventions Not Available Not Available completed NCT05222555
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients treatment 1 / 2 active_not_recruiting NCT05208853
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma No drug interventions treatment 0 unknown_status NCT05673447
The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma treatment 0 recruiting NCT05611853
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies treatment 1 / 2 terminated NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies treatment 1 recruiting NCT05907447
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No drug interventions Not Available Not Available not_yet_recruiting NCT05831865
Frontline of ASCT in High-risk DLBCL No drug interventions Not Available Not Available recruiting NCT05887167
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 recruiting NCT05887726
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors treatment 2 not_yet_recruiting NCT05875428
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 recruiting NCT05863845
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL treatment Not Available not_yet_recruiting NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas treatment 2 active_not_recruiting NCT04432402
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma treatment Not Available recruiting NCT04438005
A Study of ICP-022 in Patients With R/R DLBCL No drug interventions treatment 2 completed NCT03147885
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma treatment 1 / 2 recruiting NCT03399513
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma treatment 2 completed NCT03383406
A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma treatment 2 enrolling_by_invitation NCT03365791
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies treatment 2 completed NCT03145064
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma prevention 2 completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT03274492
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma treatment 3 active_not_recruiting NCT03276468
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas treatment 2 completed NCT03200015
Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma treatment 2 completed NCT03242902
To Decrease Fatigue With Light Therapy No drug interventions treatment 3 completed NCT03259529
Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL treatment 1 / 2 completed NCT03129828
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 treatment 1 / 2 active_not_recruiting NCT03123393
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) No drug interventions treatment 2 terminated NCT03132584
Cyclophosphamide and Alemtuzumab In Lymphoma treatment 1 terminated NCT03104478
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) No drug interventions Not Available Not Available completed NCT03072771
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) treatment 1 completed NCT05429268
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) treatment 3 recruiting NCT02734771
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 active_not_recruiting NCT02767674
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma treatment 3 unknown_status NCT02842931
R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis No drug interventions treatment 3 unknown_status NCT02951728
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma treatment 1 / 2 unknown_status NCT02955628
RICE-ibrutinib in Relapsed DLBCL treatment 2 unknown_status NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia treatment 2 recruiting NCT02747732
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL treatment 2 unknown_status NCT03036904
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas treatment 1 completed NCT03010982
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors treatment 1 completed NCT03019666
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL treatment 1 completed NCT02951156
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) treatment 3 terminated NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma No drug interventions basic_science Not Available completed NCT02660710
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma treatment 2 completed NCT02564744
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL treatment 2 completed NCT02481310
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma treatment 1 / 2 unknown_status NCT02412267
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 completed NCT02595242
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma treatment 1 withdrawn NCT02449265
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma treatment 3 recruiting NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL treatment 2 recruiting NCT02483000
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies treatment 1 terminated NCT02431988
Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation treatment 1 completed NCT02471911
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma treatment 1 completed NCT02329080
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement treatment 2 completed NCT02340936
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma treatment 1 / 2 completed NCT02268045
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma treatment 3 completed NCT02362997
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL treatment 2 completed NCT02361346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL No drug interventions treatment 1 / 2 terminated NCT02229981
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma treatment 1 / 2 withdrawn NCT02128061
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ treatment 3 completed NCT02054559
R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL treatment 3 withdrawn NCT02060656
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) treatment 2 unknown_status NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases treatment Not Available recruiting NCT01965977
Bortezomib Maintenance in High Risk DLBCL basic_science 2 unknown_status NCT01953692
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) treatment 1 completed NCT01851551
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL treatment 1 / 2 completed NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies treatment 2 terminated NCT01793233
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas No drug interventions Not Available Not Available completed NCT01791595
A Phase I Trial of AZD3965 in Patients With Advanced Cancer No drug interventions treatment 1 completed NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency No drug interventions treatment Not Available recruiting NCT01793844
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients No drug interventions Not Available Not Available unknown_status NCT01741792
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 completed NCT01713582
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) treatment 1 completed NCT01724294
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma No drug interventions Not Available Not Available terminated NCT01715961
Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma No drug interventions diagnostic Not Available completed NCT01691898
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) treatment 1 / 2 completed NCT01626352
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy treatment 2 completed NCT01653067
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma treatment 2 unknown_status NCT01606605
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT01562990
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse treatment 1 / 2 completed NCT01534949
Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial treatment 1 terminated NCT01510184
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy treatment 3 terminated NCT01502982
Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) treatment 2 completed NCT01481129
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma No drug interventions treatment 2 completed NCT01472887
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients treatment 2 completed NCT01483664
Communication Skills Intervention to Promote Transition Into Survivorship No drug interventions Not Available Not Available active_not_recruiting NCT01459887
Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma treatment 3 completed NCT01466868
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma No drug interventions treatment 2 terminated NCT01453205
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 completed NCT01402440
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma treatment 1 terminated NCT01361191
Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma No drug interventions treatment 2 completed NCT01314014
Imexon for Relapsed Follicular and Aggressive Lymphomas treatment 2 completed NCT01278602
R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma treatment 2 unknown_status NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant treatment 3 completed NCT01197560
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 / 3 completed NCT01186978
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma No drug interventions treatment Not Available completed NCT01144403
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. treatment 2 terminated NCT01122472
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP treatment 3 completed NCT01101581
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL treatment 1 / 2 withdrawn NCT00978432
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 terminated NCT00968331
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 terminated NCT00850512
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy treatment 2 completed NCT00836173
Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma No drug interventions treatment 2 withdrawn NCT00842595
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas treatment 2 completed NCT00794638
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma treatment 1 completed NCT00807495
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer treatment 1 / 2 completed NCT00776802
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 1 / 2 withdrawn NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignancies treatment 1 completed NCT00607854
Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) treatment 2 completed NCT00599170
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma treatment 2 completed NCT00575406
Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma treatment 2 completed NCT00556127
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma treatment 2 completed NCT00530179
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma treatment Not Available completed NCT00440583
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP treatment 2 completed NCT00355199
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. treatment 3 completed NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 3 completed NCT00022971
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia treatment 1 terminated NCT05179733
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years treatment 3 recruiting NCT04025593
Biomarker Guided Treatment in DLBCL treatment 2 unknown_status NCT04026100
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma No drug interventions treatment 1 unknown_status NCT03064867
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT03042247
Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma No drug interventions Not Available Not Available unknown_status NCT06552572
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy treatment 2 not_yet_recruiting NCT06517004
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma No drug interventions treatment 1 recruiting NCT06244368
GVM±R in Patients With Relapsed or Refractory Aggressive NHL. No drug interventions treatment 2 recruiting NCT06227026
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies No drug interventions treatment 1 recruiting NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT06141772
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy No drug interventions other Not Available not_yet_recruiting NCT06031194
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma No drug interventions Not Available Not Available recruiting NCT06004167
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) No drug interventions treatment Not Available recruiting NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies treatment 1 not_yet_recruiting NCT05952024
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL treatment 2 recruiting NCT05823701
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients treatment 2 recruiting NCT05816746
Decitabine and Anti-PD-1 in R/R DLBCL treatment 2 recruiting NCT05777369
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma treatment Not Available not_yet_recruiting NCT05626322
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma treatment 1 / 2 active_not_recruiting NCT05498220
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT05351346
Genotype-guided Treatment in DLBCL treatment 3 recruiting NCT05113576
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL No drug interventions Not Available Not Available completed NCT05040555
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden No drug interventions treatment Not Available recruiting NCT05054426
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL treatment 3 recruiting NCT05018520
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk treatment 3 recruiting NCT04844086
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies No drug interventions treatment 1 terminated NCT04824092
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients treatment 3 active_not_recruiting NCT04827004
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma treatment 2 unknown_status NCT04812691
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma No drug interventions treatment 1 completed NCT04804865
Secondary Prognostic Index in RefrActory Lymphoma No drug interventions Not Available Not Available unknown_status NCT04981795
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL Not Available Not Available recruiting NCT04670029
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line No drug interventions prevention 3 recruiting NCT04572763
Copanlisib Plus Venetoclax in R/R DLBCL treatment 1 / 2 active_not_recruiting NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL treatment 1 / 2 active_not_recruiting NCT04545762
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma treatment 1 recruiting NCT04486872
An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection No drug interventions treatment 1 unknown_status NCT04479267
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma treatment 2 recruiting NCT04442412
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy treatment 3 recruiting NCT04381741
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma No drug interventions treatment 1 enrolling_by_invitation NCT06439173
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment No drug interventions Not Available Not Available recruiting NCT05514327
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL No drug interventions treatment Not Available recruiting NCT04236141
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). treatment 3 terminated NCT04214626
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma treatment 2 active_not_recruiting NCT04104776
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas No drug interventions treatment 1 / 2 recruiting NCT03485118
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma treatment 2 completed NCT03984448
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas treatment 2 / 3 active_not_recruiting NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL treatment 1 / 2 recruiting NCT03949062
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL treatment 2 unknown_status NCT03894618
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 completed NCT03873025
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma treatment 1 / 2 withdrawn NCT03864419
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda treatment 1 terminated NCT03742258
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma treatment 1 unknown_status NCT03715296
Lenalidomide Based Immunotherapy in the Treatment of DLBCL Not Available Not Available unknown_status NCT03719560
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma treatment 2 withdrawn NCT03719989
Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 2 unknown_status NCT04067414
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma No drug interventions treatment 1 unknown_status NCT03684694
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma treatment 1 / 2 terminated NCT03681535
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma No drug interventions treatment Not Available active_not_recruiting NCT03685344
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma treatment 1 terminated NCT03670901
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) treatment 3 terminated NCT03579082
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma treatment 4 unknown_status NCT03501576
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma Not Available Not Available recruiting NCT04546620
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 recruiting NCT06161896
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma No drug interventions Not Available Not Available recruiting NCT04628494
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL treatment 3 active_not_recruiting NCT04850495
Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma treatment 1 recruiting NCT04695366
The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT05578976
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) treatment 3 recruiting NCT05618366
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 recruiting NCT05451810
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma treatment 2 recruiting NCT05200312
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma treatment 2 recruiting NCT05189782
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT05565417
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas treatment 1 / 2 recruiting NCT05326243
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05338892
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma No drug interventions Not Available Not Available completed NCT05541341
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies No drug interventions Not Available Not Available recruiting NCT05675982
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells No drug interventions other Not Available not_yet_recruiting NCT05690191
Chidamide in Patients With Recurrent and Refractory Diffuse Large b Not Available Not Available enrolling_by_invitation NCT05757219
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy treatment 2 recruiting NCT05834426
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers No drug interventions Not Available Not Available not_yet_recruiting NCT04433182
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma treatment 2 active_not_recruiting NCT04408638
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 3 active_not_recruiting NCT06120166
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research No drug interventions treatment 0 recruiting NCT03223610
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma treatment 1 / 2 recruiting NCT03151044
R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL treatment 3 unknown_status NCT03465527
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL supportive_care 2 completed NCT03422523
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy treatment 2 terminated NCT03376958
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma treatment 4 completed NCT03364439
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients No drug interventions treatment 2 completed NCT03375619
Long-term Follow-up Study of Patients Receiving CAR-T Cells No drug interventions Not Available Not Available recruiting NCT03349346
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents treatment 1 withdrawn NCT03311958
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance treatment 0 active_not_recruiting NCT04300101
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) No drug interventions Not Available Not Available unknown_status NCT03297424
A Study of PLX2853 in Advanced Malignancies. No drug interventions treatment 1 completed NCT03263026
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ treatment 3 completed NCT03255018
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas treatment 2 completed NCT02733380
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma treatment 2 unknown_status NCT02752204
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma treatment 2 completed NCT02753062
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma treatment 2 unknown_status NCT02772822
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients treatment 3 unknown_status NCT02792491
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over treatment 2 unknown_status NCT02867566
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients treatment 3 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients prevention 2 terminated NCT02885623
Role of CX3CR1-expressing Cells in Hematologic Malignancy No drug interventions Not Available Not Available unknown_status NCT03000738
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas No drug interventions Not Available Not Available unknown_status NCT03000192
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life No drug interventions Not Available Not Available unknown_status NCT03022123
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma treatment Not Available unknown_status NCT02763319
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 / 3 completed NCT03226704
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing No drug interventions Not Available Not Available enrolling_by_invitation NCT02871869
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma treatment 2 / 3 unknown_status NCT02700022
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas treatment 1 terminated NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 2 withdrawn NCT02531308
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) treatment 2 terminated NCT02631044
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) treatment 1 completed NCT02420210
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma treatment 2 terminated NCT02474550
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT02323230
A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL treatment 2 terminated NCT02252146
Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation treatment 1 / 2 completed NCT02142530
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL treatment 1 completed NCT01990144
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL treatment 2 unknown_status NCT01944943
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia treatment 2 terminated NCT01865058
The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma. No drug interventions Not Available Not Available unknown_status NCT01852435
R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B No drug interventions treatment 3 unknown_status NCT01842672
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia treatment 1 / 2 completed NCT01804127
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL treatment 2 unknown_status NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies treatment 2 terminated NCT01760226
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies treatment 0 completed NCT01660776
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology No drug interventions Not Available Not Available completed NCT01622439
Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma treatment 1 / 2 completed NCT01523834
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT treatment 2 completed NCT01481272
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients treatment 2 completed NCT01415765
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma treatment 1 / 2 withdrawn NCT01397825
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine treatment 1 / 2 completed NCT01340443
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma No drug interventions Not Available Not Available completed NCT01282476
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma treatment 2 terminated NCT01277172
TREatment of degeNerative and Neoplastic Diseases With Rituximab treatment 2 / 3 unknown_status NCT01287741
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) treatment 3 terminated NCT01238692
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) treatment 2 completed NCT01241734
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL treatment 1 / 2 completed NCT01004991
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma treatment 1 / 2 completed NCT00924326
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma treatment 1 / 2 completed NCT00846157
Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients No drug interventions treatment 3 unknown_status NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT00558220
R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas No drug interventions treatment 2 completed NCT00499018
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma treatment 3 unknown_status NCT00466258
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) treatment 4 completed NCT00333008
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. treatment 2 unknown_status NCT03837873
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma treatment 2 unknown_status NCT04023916
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. treatment 2 unknown_status NCT02531841
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma treatment 3 unknown_status NCT04994587
Study of LUCAR-20S in Patients With R/R NHL No drug interventions treatment 1 recruiting NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT05364424
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma treatment 1 active_not_recruiting NCT05406401
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) treatment 2 active_not_recruiting NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma treatment 3 recruiting NCT06526793
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL No drug interventions treatment 2 not_yet_recruiting NCT04488354
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T No drug interventions other 1 enrolling_by_invitation NCT00482053
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT treatment 2 terminated NCT02983097
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP treatment 1 / 2 terminated NCT05532761
Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells No drug interventions Not Available Not Available not_yet_recruiting NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients treatment 1 / 2 recruiting NCT04537715
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels treatment 1 completed NCT03547115
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML treatment 1 recruiting NCT00001337
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma treatment 2 completed NCT02570542
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 active_not_recruiting NCT04049513
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) treatment 1 active_not_recruiting NCT04933617
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas treatment 1 terminated NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies treatment 1 recruiting NCT05366257
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) No drug interventions Not Available Not Available completed NCT05619367
A Compassionate Use (CU) Program of Odronextamab Not Available Not Available available NCT01054781
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 completed NCT04456023
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) treatment 2 withdrawn NCT04767308
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies treatment 0 unknown_status NCT03936153
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 recruiting NCT05596097
Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission treatment 2 not_yet_recruiting NCT06043011
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms No drug interventions Not Available Not Available recruiting NCT04624893
A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin Not Available Not Available unknown_status NCT00400478
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 treatment 3 completed NCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 terminated NCT03601442
CTL019 Out of Specification MAP for ALL or DLBCL Patients Not Available Not Available available NCT05583149
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas treatment 2 recruiting NCT02957019
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 1 / 2 terminated NCT02544724
NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy treatment 2 unknown_status NCT01829958
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy treatment Not Available active_not_recruiting NCT02445248
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients treatment 2 completed NCT02875548
A Study to Assess the Long-term Safety of Tazemetostat treatment 1 / 2 enrolling_by_invitation NCT01066429
DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma treatment 2 unknown_status NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies treatment 1 not_yet_recruiting NCT05349201
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) No drug interventions Not Available Not Available completed NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies treatment 1 completed NCT02914938
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma treatment 1 terminated NCT03450343
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma treatment 1 completed NCT01448096
Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma treatment 2 completed NCT01410630
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma Not Available Not Available completed NCT03804372
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide treatment 2 unknown_status NCT03207867
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma treatment 2 terminated NCT03869619
REal World Data in LYmphoma and Survival in Adults No drug interventions Not Available Not Available recruiting NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies treatment 1 active_not_recruiting NCT06594432
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement treatment 2 not_yet_recruiting NCT06594939
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma treatment 2 not_yet_recruiting NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies treatment 1 recruiting NCT05934084
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors No drug interventions other Not Available recruiting NCT05234684
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma treatment 3 recruiting NCT05131022
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies No drug interventions treatment 1 recruiting NCT06050694
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) other 2 not_yet_recruiting NCT04824794
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies treatment 1 / 2 recruiting NCT05169489
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 recruiting NCT04450069
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No drug interventions treatment 1 completed NCT05366569
Bio-CAR-T BS Study No drug interventions Not Available Not Available recruiting NCT01148446
R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL treatment 3 completed NCT04231747
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma No drug interventions treatment 1 completed NCT05189197
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression treatment 2 active_not_recruiting NCT03571828
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma No drug interventions treatment 1 terminated NCT05641428
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL No drug interventions treatment 2 recruiting NCT06220032
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma treatment 3 recruiting NCT06592846
FERtility After Therapy with Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up No drug interventions Not Available Not Available not_yet_recruiting NCT05950802
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta treatment 1 recruiting NCT05487651
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies No drug interventions treatment 1 recruiting NCT06287398
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL treatment 2 recruiting NCT06158399
AZA Combined With RCHOP in P53-mutated DLBCL. treatment 2 recruiting NCT05621096
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT06526065
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) No drug interventions Not Available Not Available recruiting NCT06151080
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL treatment 2 recruiting NCT06026644
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life No drug interventions Not Available Not Available active_not_recruiting NCT06299553
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) No drug interventions Not Available Not Available recruiting NCT06026488
Real-World Study of DLBCL With Different Genetic Subtypes No drug interventions Not Available Not Available not_yet_recruiting NCT04889716
CAR-T Followed by Bispecific Antibodies treatment 2 recruiting NCT06481826
Glofitamab in Chinese Patients With R/R DLBCL Not Available Not Available recruiting NCT06534762
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study treatment 2 recruiting NCT05940272
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers No drug interventions Not Available Not Available recruiting NCT06120504
A Safety Study of SGN-35T in Adults With Advanced Cancers No drug interventions treatment 1 recruiting NCT06254495
A Safety Study of SGN-35C in Adults With Advanced Cancers No drug interventions treatment 1 recruiting NCT00529503
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL treatment 2 terminated NCT03483103
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) treatment 2 completed NCT06003179
Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah treatment 1 recruiting NCT05923879
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma Not Available Not Available not_yet_recruiting NCT01357733
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients No drug interventions diagnostic Not Available unknown_status NCT06573645
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL treatment 3 not_yet_recruiting NCT04022005
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL treatment 2 completed NCT05263583
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma treatment 2 recruiting NCT02928861
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma No drug interventions diagnostic Not Available unknown_status NCT05199961
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel No drug interventions supportive_care Not Available terminated NCT05798156
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP treatment 2 active_not_recruiting NCT01649856
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma treatment 3 completed NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors treatment 1 / 2 terminated NCT00901615
Lenalidomide and R-CHOP in B-cell Lymphoma treatment 1 / 2 completed NCT05784415
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell No drug interventions Not Available Not Available active_not_recruiting NCT00001237
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas No drug interventions treatment 2 completed NCT00822432
Coproporphyrine Isomers and Methotrexate Elimination No drug interventions Not Available Not Available completed NCT03016000
Thalidomide Maintenance Treatment in DLBCL treatment 3 unknown_status NCT02987400
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL treatment 2 completed NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies treatment 1 terminated NCT04660799
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) treatment 2 completed NCT00135499
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma treatment 3 terminated NCT02376699
Safety Study of SEA-CD40 in Cancer Patients treatment 1 terminated NCT04317313
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT05466318
ChiCGB vs BEAM in High-risk or R/R Lymphomas treatment 3 recruiting NCT02181218
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas treatment 1 completed NCT00823719
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) treatment 2 completed NCT03310619
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies treatment 1 / 2 completed NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) treatment 1 completed NCT04789434
PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT treatment 3 unknown_status NCT01421524
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma treatment 1 completed NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) treatment 2 active_not_recruiting NCT00435916
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma treatment 2 completed NCT02278796
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) No drug interventions treatment 2 completed NCT01786135
A Safety Study of SGN-CD19A for B-Cell Lymphoma treatment 1 completed NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies No drug interventions treatment Not Available terminated NCT03646422
AEDV Registry of Primary Cutaneous Lymphoma No drug interventions Not Available Not Available recruiting NCT05327725
Fatigue Reduction Diet in Lymphoma Survivors No drug interventions treatment Not Available completed NCT03018626
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL treatment 3 unknown_status NCT05800366
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT03003520
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma treatment 2 completed NCT03293173
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis No drug interventions treatment 2 active_not_recruiting NCT03357627
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma other 1 completed NCT00864227
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) No drug interventions treatment 2 completed NCT03744676
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) treatment 2 completed NCT04446962
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) treatment 1 / 2 recruiting NCT03135262
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) treatment 1 / 2 terminated NCT02653989
Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No drug interventions treatment 2 withdrawn NCT02624492
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL treatment 2 completed NCT04214444
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab other 3 unknown_status NCT02555267
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT02931201
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma No drug interventions diagnostic Not Available unknown_status NCT02086604
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma treatment 1 completed NCT02743546
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma treatment 1 withdrawn NCT01925612
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 terminated NCT00137995
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma treatment 3 completed NCT04799314
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT treatment 3 unknown_status NCT03977623
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression No drug interventions Not Available Not Available unknown_status NCT01014208
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma treatment 3 completed NCT00498043
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma No drug interventions treatment 2 completed NCT00511043
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma treatment 2 terminated NCT04790903
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) treatment 1 terminated NCT03211702
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) No drug interventions Not Available Not Available completed NCT02846584
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies No drug interventions treatment 2 unknown_status NCT00561379
Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab treatment Not Available completed NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas treatment 2 terminated NCT02428751
R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma treatment 3 unknown_status NCT00849147
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) No drug interventions treatment 2 completed NCT04982471
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study No drug interventions Not Available Not Available recruiting NCT00622388
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant treatment 2 completed NCT01157988
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma treatment 2 completed NCT02737085
the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) No drug interventions treatment 1 / 2 unknown_status NCT02417285
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. treatment 1 completed NCT02208037
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) prevention 2 completed NCT00655837
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL treatment 1 completed NCT05728632
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines prevention 3 active_not_recruiting NCT06289959
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL No drug interventions treatment Not Available not_yet_recruiting NCT00532259
CT-011 MAb in DLBCL Patients Following ASCT treatment 2 completed NCT01156259
30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy No drug interventions treatment 3 unknown_status NCT01181999
Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma treatment 2 unknown_status NCT03049449
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas treatment 1 completed NCT02343536
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma treatment 1 completed NCT00006436
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection treatment 2 completed NCT00322218
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. treatment 3 terminated NCT03373019
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) treatment 2 unknown_status NCT02031419
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma treatment 1 terminated NCT06093841
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL treatment 2 not_yet_recruiting NCT03241017
Durvalumab in DLBCL After Autologous Transplant treatment 2 withdrawn NCT02883517
Cell-free Circulating DNA in Primary Cutaneous Lymphomas No drug interventions Not Available Not Available completed NCT01324596
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib treatment 3 completed NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma No drug interventions treatment 1 completed NCT05186558
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL treatment 2 not_yet_recruiting NCT03600363
A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients treatment 2 unknown_status NCT03536039
RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor treatment 2 completed NCT00582725
R-CHOP + GM-CSF for Previously Untreated LCL in Elderly treatment 2 completed NCT00169130
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma treatment 2 / 3 completed NCT04763148
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA No drug interventions Not Available Not Available completed NCT00379574
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL treatment 1 / 2 completed NCT03629873
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects treatment 2 unknown_status NCT02592876
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma treatment 2 terminated NCT02776891
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma diagnostic 2 withdrawn NCT04400591
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Not Available Not Available available NCT05318391
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma No drug interventions Not Available Not Available completed NCT02285062
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma treatment 3 completed NCT00436280
Chemotherapy for Participants With Lymphoma treatment 2 completed NCT02413489
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma treatment 2 terminated NCT04021992
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL No drug interventions treatment 2 unknown_status NCT01421667
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma treatment 2 completed NCT01307267
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab treatment 1 completed NCT04237168
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL) No drug interventions Not Available Not Available unknown_status NCT01266668
The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) No drug interventions Not Available Not Available completed NCT00689169
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma treatment 2 completed NCT04183569
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma No drug interventions Not Available Not Available unknown_status NCT04271410
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma No drug interventions treatment 1 / 2 recruiting NCT03154710
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response No drug interventions diagnostic Not Available terminated NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT00498914
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects treatment 2 terminated NCT02364050
Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM No drug interventions Not Available Not Available unknown_status NCT03910283
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT01325701
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma treatment 2 completed